Baseline Tumor Biology Predicts Survival After Recurrence in Gastric Cancer: Impact of LVI, PNI, and HER2 Status
Medical Science Monitor · 2026
DOI: 10.12659/msm.951829 ↗Kurz gefasst
Fachartikel in der Zeitschrift Medical Science Monitor, 2026. Verfasst von Gözde Ağdaş und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Van Training and Research Hospital, Van, Turkey. Hauptthemen laut MEDLINE: Stomach Neoplasms, Erb-b2 Receptor Tyrosine Kinases. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, Van Training and Research Hospital, Van, Turkey.
ORCID-Profile: Gözde Ağdaş, Mehmet Salim Demir
Zitieren
APA
Ağdaş, G., & Demir, M. S. (2026). Baseline Tumor Biology Predicts Survival After Recurrence in Gastric Cancer: Impact of LVI, PNI, and HER2 Status. Medical Science Monitor. https://doi.org/10.12659/msm.951829
Vancouver
Ağdaş G, Demir MS. Baseline Tumor Biology Predicts Survival After Recurrence in Gastric Cancer: Impact of LVI, PNI, and HER2 Status. Medical Science Monitor. 2026. doi:10.12659/msm.951829
BibTeX
@article{Ada2026,
author = {Ağdaş, Gözde and Demir, Mehmet Salim},
title = {Baseline Tumor Biology Predicts Survival After Recurrence in Gastric Cancer: Impact of LVI, PNI, and HER2 Status},
journal = {Medical Science Monitor},
year = {2026},
doi = {10.12659/msm.951829}
}
EUVIMED